Transport
Hca Health Services of New Hampshire INC
Hca Health Services of New Hampshire INC was paid $18.83M by Medicaid between Jan 2018 and Dec 2024, across 165 billing codes. Its largest line is 99283, emergency room visit (moderate) — 35% of everything it billed.
33Billing provider infoHCA HEALTH SERVICES OF NEW HAMPSHIRE INC
PORTSMOUTH, NH 03801
PORTSMOUTH, NH 03801
33aNPI1518913607assigned 05/26/2006
33bProvider typeAmbulance
28Total paid$18.83M
24GClaims354,981
24DCodes billed165
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Ambulance providers in New Hampshire
Rank by total paid#1 of 43
Median peer was paid$37K
This provider vs. median514×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 53,132 | $2.54M | |
| 2019 | 61,160 | $2.70M | |
| 2020 | 56,914 | $2.79M | |
| 2021 | 82,131 | $3.93M | |
| 2022 | 62,055 | $3.87M | |
| 2023 | 24,003 | $1.69M | |
| 2024incomplete | 15,586 | $1.32M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 35% | 32,057 | 26,464 | $6.50M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 22% | 18,571 | 14,362 | $4.15M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 7.5% | 3,729 | 2,751 | $1.41M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 7.2% | 7,778 | 6,661 | $1.36M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 5.1% | 2,744 | 2,205 | $964K |
| 70450 | Computed tomography, head or brain; without contrast material | 3.0% | 3,377 | 2,557 | $561K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 2.1% | 10,537 | 7,937 | $395K |
| G0378 | Hospital observation service, per hour | 1.9% | 2,127 | 969 | $359K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 1.3% | 1,656 | 1,346 | $250K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.1% | 9,308 | 6,655 | $198K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 4,428 | 3,203 | $159K |
| 80053 | Comprehensive metabolic panel | <1% | 24,057 | 17,608 | $157K |
153 more codes
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 4,156 | $131K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 673 | $122K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 695 | $114K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 550 | $103K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 347 | $96K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 923 | $95K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 4,068 | $92K |
| 85027 | <1% | 31,589 | $89K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 3,025 | $83K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 2,416 | $81K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 3,629 | $80K |
| 41899 | Unlisted procedure, dentoalveolar structures | <1% | 53 | $74K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 5,235 | $72K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 748 | $68K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 4,506 | $66K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 4,719 | $48K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 5,392 | $46K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 1,009 | $40K |
| 71045 | Radiologic examination, chest; single view | <1% | 4,593 | $38K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,094 | $35K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 70 | $32K |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 1,815 | $29K |
| 84484 | <1% | 6,567 | $27K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 2,045 | $27K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 267 | $26K |
| 93971 | <1% | 258 | $25K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 1,000 | $24K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 4,235 | $19K |
| 97163 | <1% | 756 | $19K | |
| 73630 | <1% | 484 | $17K | |
| 80061 | Lipid panel | <1% | 2,127 | $17K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 1,538 | $16K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 4,746 | $16K |
| A0425 | Ground mileage, per statute mile | <1% | 332 | $16K |
| 73610 | <1% | 436 | $15K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 24 | $14K |
| 83690 | <1% | 4,724 | $14K | |
| 84703 | <1% | 2,736 | $14K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 3,965 | $13K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 85 | $13K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 2,142 | $13K |
| 83735 | <1% | 4,536 | $12K | |
| 81025 | <1% | 2,919 | $11K | |
| 76830 | Ultrasound, transvaginal | <1% | 176 | $11K |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 394 | $11K |
| 82077 | <1% | 1,665 | $10K | |
| 83605 | <1% | 2,420 | $10K | |
| 80076 | <1% | 2,496 | $10K | |
| 87040 | <1% | 1,862 | $10K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 593 | $10K |
| 73130 | <1% | 279 | $9K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,787 | $9K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,567 | $8K |
| 81003 | <1% | 7,042 | $8K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 173 | $8K |
| 83880 | <1% | 719 | $8K | |
| 97803 | <1% | 881 | $8K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 494 | $8K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 494 | $8K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 2,254 | $7K |
| 36415 | Collection of venous blood by venipuncture | <1% | 8,824 | $7K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 8,724 | $7K |
| A0428 | Ambulance service, basic life support, non-emergency transport, (bls) | <1% | 221 | $7K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 4,867 | $7K |
| 85610 | <1% | 4,793 | $6K | |
| 96376 | <1% | 311 | $6K | |
| 80047 | <1% | 2,243 | $6K | |
| 71250 | <1% | 37 | $6K | |
| 73030 | <1% | 189 | $6K | |
| 87081 | <1% | 1,477 | $6K | |
| 85379 | <1% | 1,313 | $6K | |
| 73562 | <1% | 341 | $6K | |
| 73110 | <1% | 158 | $5K | |
| 85730 | <1% | 2,525 | $5K | |
| 81001 | <1% | 4,496 | $5K | |
| 12001 | <1% | 27 | $5K | |
| 87186 | <1% | 1,142 | $5K | |
| 90715 | <1% | 161 | $4K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 86 | $4K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 598 | $4K |
| 82728 | <1% | 368 | $3K | |
| 72100 | <1% | 69 | $3K | |
| 87070 | <1% | 720 | $3K | |
| 82607 | <1% | 409 | $3K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 2,065 | $3K |
| 83550 | <1% | 567 | $3K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 224 | $3K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,084 | $3K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 14 | $3K |
| 86140 | <1% | 889 | $3K | |
| 76775 | <1% | 43 | $3K | |
| ATP14 | <1% | 258 | $3K | |
| 84100 | <1% | 1,314 | $2K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 1,777 | $2K |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 241 | $2K |
| 87077 | <1% | 668 | $2K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 101 | $2K |
| 83540 | <1% | 589 | $2K | |
| A9270 | Non-covered item or service | <1% | 10,762 | $2K |
| J3490 | Unclassified drugs | <1% | 1,276 | $2K |
| 87147 | <1% | 741 | $2K | |
| 80179 | <1% | 256 | $2K | |
| 87205 | <1% | 745 | $2K | |
| 80143 | <1% | 278 | $2K | |
| S0119 | Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) | <1% | 928 | $2K |
| 10060 | <1% | 13 | $2K | |
| 84439 | <1% | 313 | $2K | |
| 85652 | <1% | 993 | $2K | |
| 97162 | <1% | 34 | $1K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,578 | $1K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 893 | $1K |
| C1769 | Guide wire | <1% | 21 | $1K |
| 84702 | <1% | 152 | $1K | |
| 87158 | <1% | 304 | $1K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 26 | $1K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,073 | $1K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 897 | $926.59 |
| 74018 | <1% | 102 | $917.87 | |
| 82746 | <1% | 100 | $890.16 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 995 | $884.52 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 16 | $876.79 |
| 87631 | <1% | 33 | $860.14 | |
| 86850 | <1% | 169 | $786.54 | |
| 87807 | <1% | 128 | $776.28 | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 21 | $764.19 |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 435 | $731.32 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 958 | $625.25 |
| 86618 | <1% | 31 | $549.01 | |
| 86900 | <1% | 358 | $526.37 | |
| 86901 | <1% | 358 | $494.69 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 799 | $454.22 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 443 | $428.00 |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 128 | $392.54 |
| 73502 | <1% | 15 | $266.94 | |
| J2704 | Injection, propofol, 10 mg | <1% | 797 | $260.34 |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 59 | $251.33 |
| 97035 | <1% | 34 | $217.63 | |
| 82570 | <1% | 51 | $136.90 | |
| 86803 | <1% | 13 | $130.22 | |
| 82150 | <1% | 30 | $112.48 | |
| 82330 | <1% | 43 | $63.21 | |
| 82248 | <1% | 38 | $48.49 | |
| 86308 | <1% | 12 | $43.59 | |
| 82565 | <1% | 34 | $42.00 | |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 67 | $40.24 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 16 | $36.38 |
| 81015 | <1% | 15 | $19.53 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 15 | $12.97 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 17 | $12.40 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 131 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 171 | $0.00 |
| G1003 | Clinical decision support mechanism medicalis, as defined by the medicare appropriate use criteria program | 0% | 193 | $0.00 |
| G1011 | Clinical decision support mechanism, qualified tool not otherwise specified, as defined by the medicare appropriate use criteria program | 0% | 48 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialBIGGERS, HALEY (CFO)
| Provider | Location | Paid |
|---|---|---|
| Springfield Health Services, LLC | Springfield, TN | $3.92M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.